Lucitanib | E-3810 | VEGFR/FGFR Inhibitor | AmBeed-信号通路专用抑制剂

Lucitanib/德立替尼 {[allProObj[0].p_purity_real_show]}

货号：A410196 同义名： E-3810; Lucitanib hydrochloride

Lucitanib是一种 VEGFR 和 FGFR 的双重抑制剂，能强效选择性抑制 VEGFR1、VEGFR2、VEGFR3、FGFR1 和 FGFR2，IC50 分别为 7 nM、25 nM、10 nM、17.5 nM 和 82.5 nM。

Lucitanib/德立替尼化学结构
CAS号：1058137-23-7

Lucitanib/德立替尼 3D分子结构
CAS号：1058137-23-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

FGFR 亚型比较

VEGFR 亚型比较

产品名称	FGFR ↓ ↑	FGFR1 ↓ ↑	FGFR2 ↓ ↑	FGFR3 ↓ ↑	FGFR4 ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ FGFR (Swiss 3T3), IC50: 12.3 μM					PDGFR	99%+
Pazopanib	+ FGFR, IC50: 140 nM						99%
Erdafitinib	✔					RET	99%+
Gambogenic acid	✔						98+%
Sulfatinib		+++ FGFR1, IC50: 15 nM					99+%
Nintedanib esylate		+ FGFR1, IC50: 69 nM	++ FGFR2, IC50: 37 nM	+ FGFR3, IC50: 108 nM			98%
Zoligratinib		+++ FGFR1, IC50: 9.3 nM	+++ FGFR2, IC50: 7.6 nM	++ FGFR3, IC50: 22 nM	+ FGFR4, IC50: 290 nM		99%+
MK-2461		+ FGFR1, IC50: 65 nM	++ FGFR2, IC50: 39 nM	++ FGFR3, IC50: 50 nM			98%+
SU 5402		++ FGFR1, IC50: 30 nM					98%
Brivanib		+ FGFR1, IC50: 148 nM					99%+
Lucitanib		++ FGFR1, IC50: 17.5 nM	+ FGFR2, IC50: 82.5 nM				99%+
Ponatinib		++++ FGFR1, IC50: 2.2 nM					98%
PD-166866		+ FGFR1, IC50: 52.4 nM					99%
Narazaciclib		++ FGFR1, IC50: 26 nM				RET	99%+
Lactate		+++ FGFR1, IC50: 8 nM		+++ FGFR3, IC50: 9 nM		FLT3,c-Kit	85%
Lenvatinib mesylate		++ FGFR1, IC50: 46 nM				c-RET	99%
LY2874455		++++ FGFR1, IC50: 2.8 nM	++++ FGFR2, IC50: 2.6 nM	+++ FGFR3, IC50: 6.4 nM	+++ FGFR4, IC50: 6 nM		99%+
FIIN-2		+++ FGFR1, IC50: 3.09 nM	+++ FGFR2, IC50: 4.3 nM	++ FGFR3, IC50: 27 nM	++ FGFR4, IC50: 45.3 nM		99%
FIIN-3		+++ FGFR1, IC50: 13.1 nM	++ FGFR2, IC50: 21 nM	++ FGFR3, IC50: 31.4 nM	++ FGFR4, IC50: 35.3 nM		98%
Infigratinib		++++ FGFR1, IC50: 0.9 nM	++++ FGFR2, IC50: 1.4 nM	++++ FGFR3, IC50: 1.0 nM FGFR3 (K650E), IC50: 4.9 nM	+ FGFR4, IC50: 60 nM		99%+
Danusertib		++ FGFR1, IC50: 47 nM				RET	99%+
R1530		++ FGFR1, IC50: 28 nM					98%
ENMD-2076		+ FGFR1, IC50: 92.7 nM	+ FGFR2, IC50: 70.8 nM			RET,FLT3	98%
Dovitinib		+++ FGFR1, IC50: 8 nM		+++ FGFR3, IC50: 9 nM		FLT3,c-Kit	99%+
Sorafenib		+ FGFR1, IC50: 580 nM					99%
SSR128129E		+ FGFR1, IC50: 1.9 μM					99%+
AZD-4547		++++ FGFR1, IC50: 0.2 nM	++++ FGFR2, IC50: 2.5 nM	++++ FGFR3, IC50: 1.8 nM			98%
Lenvatinib		++ FGFR1, IC50: 46 nM				RET	98%
PD173074		++ FGFR1, IC50: ~25 nM					99%+
S49076		++ FGFR1, IC50: 18 nM	+++ FGFR2, IC50: 17 nM	+++ FGFR3, IC50: 15 nM			98%
Futibatinib		++++ FGFR1, IC50: 1.8 nM	++++ FGFR2, IC50: 1.4 nM	++++ FGFR3, IC50: 1.6 nM	+++ FGFR4, IC50: 3.7 nM		99%+
Ferulic Acid		+ FGFR1, IC50: 3.78 μM	+ FGFR2, IC50: 12.5 μM				98%
Nintedanib		+ FGFR1, IC50: 69 nM	++ FGFR2, IC50: 37 nM	+ FGFR3, IC50: 108 nM	+ FGFR4, IC50: 610 nM		99+%
ASP5878		++++ FGFR1, IC50: 0.47 nM	++++ FGFR2, IC50: 0.6 nM	++++ FGFR3, IC50: 0.74 nM	+++ FGFR4, IC50: 3.5 nM		99%
PRN1371		++++ FGFR1, IC50: 0.6 nM	++++ FGFR2, IC50: 1.3 nM	+++ FGFR3, IC50: 4.1 nM	++ FGFR4, IC50: 19.3 nM		99%
Derazantinib		+++ FGFR1, IC50: 4.5 nM	++++ FGFR2, IC50: 1.8 nM	+++ FGFR3, IC50: 4.5 nM	++ FGFR4, IC50: 34 nM	RET	99%+
ODM-203		+++ FGFR1, IC50: 11 nM	+++ FGFR2, IC50: 16 nM	+++ FGFR3, IC50: 6 nM	++ FGFR4, IC50: 35 nM		99%+
Pemigatinib		++++ FGFR1, IC50: 0.4 nM	++++ FGFR2, IC50: 0.5 nM	++++ FGFR3, IC50: 1.2 nM	++ FGFR4, IC50: 30 nM		99%+
SKLB 610			✔			PDGFR	99%+
Alofanib			✔				99%+
Lirafugratinib			✔				99%
Masitinib mesylate				✔		FAK	99%+
BLU9931				+ FGFR3, IC50: 150 nM	+++ FGFR4, IC50: 3 nM		99%+
BO-264				✔			99%+
Fisogatinib					+++ FGFR4, IC50: 5 nM		99%+
H3B-6527					++++ FGFR4, IC50: <1.2 nM		99%+
Roblitinib					++++ FGFR4, IC50: 1.9 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,PDGFR,c-Kit	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Fms/CSF1R,c-Kit	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ hVEGFR2, IC50: 9 nM mVEGF2, IC50: 165 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Lucitanib/德立替尼生物活性

靶点

FGFR2

FGFR2, IC50:82.5 nM
FGFR1

FGFR1, IC50:17.5 nM

描述

E-3810 is a dual inhibitor of the VEGF and FGF receptors, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

Lucitanib/德立替尼细胞实验

Cell Line Baf3-CCDC6-RET cells TPC-1 cells SW579 cells TT cells Small cell lung cancer cell line (DMS114) Non-small cell lung cancer cell lines (H1299, H1975, H2342, H1650, H358, A549, H2228, H23, H1581, H520) CAMA1 cells T47D cells MCF-7 cells CAMA1 cells	Concentration	Treated Time	Description	References
Baf3-CCDC6-RET cells	1–10 μmol/L		AL3810 dose-dependently inhibited the proliferation of Baf3-CCDC6-RET cells with an IC50 value of 2.77 μmol/L.	Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542
TPC-1 cells	2–5 μmol/L	72 hours	AL3810 dose-dependently inhibited the proliferation of TPC-1 cells with IC50 values ranging from 0.59 to 7.03 μmol/L.	Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542
SW579 cells	2–5 μmol/L	72 hours	AL3810 dose-dependently inhibited the proliferation of SW579 cells with IC50 values ranging from 0.59 to 7.03 μmol/L.	Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542
TT cells	2–5 μmol/L	72 hours	AL3810 dose-dependently inhibited the proliferation of TT cells with IC50 values ranging from 0.59 to 7.03 μmol/L.	Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542
Small cell lung cancer cell line (DMS114)	1μM	4, 24, 48 and 72 hours	To study the effect of Lucitanib on cell cycle in FGFR1 amplified cell lines. Results showed a G1 block in DMS114 cells from 24 to 48 hours, but no apoptosis was detected.	Neoplasia. 2017 Jan;19(1):35-42
Non-small cell lung cancer cell lines (H1299, H1975, H2342, H1650, H358, A549, H2228, H23, H1581, H520)	0.01 to 50μM	72 hours	To evaluate the growth inhibitory effect of Lucitanib on cell lines with FGFR1/2 amplification or mutation. Results showed that FGFR1/2 amplified or mutated cell lines were more sensitive to Lucitanib (IC50 of 0.045–3.16μM) compared to wild-type cell lines (IC50 of 3–23μM).	Neoplasia. 2017 Jan;19(1):35-42
CAMA1 cells	1 μM	6 days	Lucitanib combined with fulvestrant/palbociclib significantly inhibited cell growth, inducing cell cycle arrest and senescence	Nat Commun. 2019 Mar 26;10(1):1373
T47D cells	1 μM	14 days	FGFR1 overexpression confers resistance to fulvestrant ± palbociclib, which was reversed by lucitanib	Nat Commun. 2019 Mar 26;10(1):1373
MCF-7 cells	1 μM	14 days	FGFR1 overexpression confers resistance to fulvestrant ± palbociclib, which was reversed by lucitanib	Nat Commun. 2019 Mar 26;10(1):1373
CAMA1 cells	2 μM	6 hours	Inhibited the association of FGFR1 with ERα and reduced ERα-dependent gene transcription	Clin Cancer Res. 2017 Oct 15;23(20):6138-6150

Cell Line

Concentration

Treated Time

Description

References

Baf3-CCDC6-RET cells

1–10 μmol/L

AL3810 dose-dependently inhibited the proliferation of Baf3-CCDC6-RET cells with an IC50 value of 2.77 μmol/L.

Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542

TPC-1 cells

2–5 μmol/L

72 hours

AL3810 dose-dependently inhibited the proliferation of TPC-1 cells with IC50 values ranging from 0.59 to 7.03 μmol/L.

Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542

SW579 cells

2–5 μmol/L

72 hours

AL3810 dose-dependently inhibited the proliferation of SW579 cells with IC50 values ranging from 0.59 to 7.03 μmol/L.

Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542

TT cells

2–5 μmol/L

72 hours

AL3810 dose-dependently inhibited the proliferation of TT cells with IC50 values ranging from 0.59 to 7.03 μmol/L.

Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542

Small cell lung cancer cell line (DMS114)

1μM

4, 24, 48 and 72 hours

To study the effect of Lucitanib on cell cycle in FGFR1 amplified cell lines. Results showed a G1 block in DMS114 cells from 24 to 48 hours, but no apoptosis was detected.

Neoplasia. 2017 Jan;19(1):35-42

Non-small cell lung cancer cell lines (H1299, H1975, H2342, H1650, H358, A549, H2228, H23, H1581, H520)

0.01 to 50μM

72 hours

To evaluate the growth inhibitory effect of Lucitanib on cell lines with FGFR1/2 amplification or mutation. Results showed that FGFR1/2 amplified or mutated cell lines were more sensitive to Lucitanib (IC50 of 0.045–3.16μM) compared to wild-type cell lines (IC50 of 3–23μM).

Neoplasia. 2017 Jan;19(1):35-42

CAMA1 cells

1 μM

6 days

Lucitanib combined with fulvestrant/palbociclib significantly inhibited cell growth, inducing cell cycle arrest and senescence

Nat Commun. 2019 Mar 26;10(1):1373

T47D cells

1 μM

14 days

FGFR1 overexpression confers resistance to fulvestrant ± palbociclib, which was reversed by lucitanib

Nat Commun. 2019 Mar 26;10(1):1373

MCF-7 cells

1 μM

14 days

FGFR1 overexpression confers resistance to fulvestrant ± palbociclib, which was reversed by lucitanib

Nat Commun. 2019 Mar 26;10(1):1373

CAMA1 cells

2 μM

6 hours

Inhibited the association of FGFR1 with ERα and reduced ERα-dependent gene transcription

Clin Cancer Res. 2017 Oct 15;23(20):6138-6150

Lucitanib/德立替尼动物实验

Species Nude mice BALB/c nude mice Female NCr-nu/nu mice Female athymic nude mice	Animal Model MCF-7FGFR1 xenograft model SW579 and TT xenograft models Lung, gastric and endometrial carcinoma xenograft models ER+/HER2-/FGFR1-amplified PDX models	Administration	Dosage	Frequency	Description	References
Nude mice	MCF-7FGFR1 xenograft model	Oral	10 mg/kg/day	Daily until tumor volume assessment	The triple therapy (fulvestrant + palbociclib + lucitanib) significantly inhibited tumor growth in FGFR1-overexpressing tumors, reducing p-RB and p-FGFR1 levels	Nat Commun. 2019 Mar 26;10(1):1373
BALB/c nude mice	SW579 and TT xenograft models	Oral	5–20 mg·kg-1·d-1	Once daily for 21 days	AL3810 significantly inhibited tumor growth in SW579 and TT xenograft models and reduced microvessel density in tumor tissues.	Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542
Female NCr-nu/nu mice	Lung, gastric and endometrial carcinoma xenograft models	Oral	2.5, 5, 10 or 20 mg/kg	Once daily for 30 days	To evaluate the antitumor activity of Lucitanib in FGFR1/2 amplified or mutated tumor models. Results showed dose-dependent tumor growth inhibition in all models, with more significant effects in FGFR1 amplified lung cancer models.	Neoplasia. 2017 Jan;19(1):35-42
Female athymic nude mice	ER+/HER2-/FGFR1-amplified PDX models	Oral	7 mg/kg/day	Once daily for 3 weeks	Combination of fulvestrant and lucitanib significantly inhibited tumor growth	Clin Cancer Res. 2017 Oct 15;23(20):6138-6150

Species

Nude mice BALB/c nude mice Female NCr-nu/nu mice Female athymic nude mice

Animal Model

MCF-7FGFR1 xenograft model SW579 and TT xenograft models Lung, gastric and endometrial carcinoma xenograft models ER+/HER2-/FGFR1-amplified PDX models

Administration

Dosage

Frequency

Description

References

Nude mice

MCF-7FGFR1 xenograft model

Oral

10 mg/kg/day

Daily until tumor volume assessment

The triple therapy (fulvestrant + palbociclib + lucitanib) significantly inhibited tumor growth in FGFR1-overexpressing tumors, reducing p-RB and p-FGFR1 levels

Nat Commun. 2019 Mar 26;10(1):1373

BALB/c nude mice

SW579 and TT xenograft models

Oral

5–20 mg·kg-1·d-1

Once daily for 21 days

AL3810 significantly inhibited tumor growth in SW579 and TT xenograft models and reduced microvessel density in tumor tissues.

Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542

Female NCr-nu/nu mice

Lung, gastric and endometrial carcinoma xenograft models

Oral

2.5, 5, 10 or 20 mg/kg

Once daily for 30 days

To evaluate the antitumor activity of Lucitanib in FGFR1/2 amplified or mutated tumor models. Results showed dose-dependent tumor growth inhibition in all models, with more significant effects in FGFR1 amplified lung cancer models.

Neoplasia. 2017 Jan;19(1):35-42

Female athymic nude mice

ER+/HER2-/FGFR1-amplified PDX models

Oral

7 mg/kg/day

Once daily for 3 weeks

Combination of fulvestrant and lucitanib significantly inhibited tumor growth

Clin Cancer Res. 2017 Oct 15;23(20):6138-6150

Lucitanib/德立替尼参考文献

Lucitanib/德立替尼实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.25mL

0.45mL

0.23mL

11.27mL

2.25mL

1.13mL

22.55mL

4.51mL

2.25mL

Lucitanib/德立替尼技术信息

CAS号	1058137-23-7
分子式	C₂₆H₂₅N₃O₄
分子量	443.49
SMILES Code	O=C(NC)C1=CC=CC2=C1C=CC(OC3=CC=NC4=CC(OCC5(N)CC5)=C(OC)C=C43)=C2
MDL No.	MFCD20527751

别名	E-3810; Lucitanib hydrochloride; AL3810
运输	蓝冰
InChI Key	CUDVHEFYRIWYQD-UHFFFAOYSA-N
Pubchem ID	25031915

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 20 mg/mL(45.1 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

Lucitanib/德立替尼 {[allProObj[0].p_purity_real_show]}

Lucitanib/德立替尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Lucitanib/德立替尼质控信息

Lucitanib/德立替尼生物活性

Lucitanib/德立替尼细胞实验

Lucitanib/德立替尼动物实验

Lucitanib/德立替尼参考文献

Lucitanib/德立替尼实验方案

Lucitanib/德立替尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

靶点	FGFR2 FGFR2, IC50:82.5 nM FGFR1 FGFR1, IC50:17.5 nM
描述	E-3810 is a dual inhibitor of the VEGF and FGF receptors, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

Lucitanib/德立替尼 {[allProObj[0].p_purity_real_show]}

Lucitanib/德立替尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Lucitanib/德立替尼 质控信息

Lucitanib/德立替尼 生物活性

Lucitanib/德立替尼 细胞实验

Lucitanib/德立替尼 动物实验

Lucitanib/德立替尼 参考文献

Lucitanib/德立替尼 实验方案

Lucitanib/德立替尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Lucitanib/德立替尼纯度/质量文件产品仅供科研

Lucitanib/德立替尼质控信息

Lucitanib/德立替尼生物活性

Lucitanib/德立替尼细胞实验

Lucitanib/德立替尼动物实验

Lucitanib/德立替尼参考文献

Lucitanib/德立替尼实验方案

Lucitanib/德立替尼技术信息